NZ540811A - Use of HPV 16 and HPV 18 VLPs in the prevention of infection or disease caused by one or more of the group of oncogenic HPV types excluding types 16 and 18 - Google Patents

Use of HPV 16 and HPV 18 VLPs in the prevention of infection or disease caused by one or more of the group of oncogenic HPV types excluding types 16 and 18

Info

Publication number
NZ540811A
NZ540811A NZ540811A NZ54081103A NZ540811A NZ 540811 A NZ540811 A NZ 540811A NZ 540811 A NZ540811 A NZ 540811A NZ 54081103 A NZ54081103 A NZ 54081103A NZ 540811 A NZ540811 A NZ 540811A
Authority
NZ
New Zealand
Prior art keywords
hpv
group
types
infection
vlps
Prior art date
Application number
NZ540811A
Other languages
English (en)
Inventor
Gary Dubin
Bruce Innis
Moncef Mohammed Slaoui
Martine Anne Cecil Wettendorff
Original Assignee
Glaxosmithkline Biolog S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog S filed Critical Glaxosmithkline Biolog S
Publication of NZ540811A publication Critical patent/NZ540811A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ540811A 2002-12-20 2003-12-18 Use of HPV 16 and HPV 18 VLPs in the prevention of infection or disease caused by one or more of the group of oncogenic HPV types excluding types 16 and 18 NZ540811A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20
PCT/EP2003/014562 WO2004056389A1 (en) 2002-12-20 2003-12-18 Hpv-16 and -18 l1 vlp vaccine

Publications (1)

Publication Number Publication Date
NZ540811A true NZ540811A (en) 2007-03-30

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ540811A NZ540811A (en) 2002-12-20 2003-12-18 Use of HPV 16 and HPV 18 VLPs in the prevention of infection or disease caused by one or more of the group of oncogenic HPV types excluding types 16 and 18

Country Status (28)

Country Link
US (2) US20060251676A1 (Direct)
EP (1) EP1572233B1 (Direct)
JP (1) JP5475939B2 (Direct)
KR (3) KR20050086924A (Direct)
AP (1) AP2005003347A0 (Direct)
AR (1) AR042530A1 (Direct)
AT (1) ATE503492T1 (Direct)
AU (1) AU2003293942B2 (Direct)
BE (3) BE2015C067I2 (Direct)
BR (1) BR0317544A (Direct)
CA (1) CA2510457C (Direct)
CY (1) CY1111552T1 (Direct)
DE (1) DE60336581D1 (Direct)
DK (1) DK1572233T3 (Direct)
EA (2) EA200701633A1 (Direct)
EC (1) ECSP055869A (Direct)
IL (1) IL169085A (Direct)
IS (1) IS2811B (Direct)
MA (1) MA27581A1 (Direct)
MX (1) MXPA05006764A (Direct)
MY (1) MY144492A (Direct)
NO (1) NO20052846L (Direct)
NZ (1) NZ540811A (Direct)
OA (1) OA13147A (Direct)
PL (1) PL215257B1 (Direct)
PT (1) PT1572233E (Direct)
TW (1) TWI349557B (Direct)
WO (1) WO2004056389A1 (Direct)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1666060A1 (en) 1998-10-16 2006-06-07 Glaxosmithkline Biologicals S.A. Adjuvant systems and vaccines
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
PE20060434A1 (es) * 2004-06-16 2006-06-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
KR20080005583A (ko) * 2005-04-26 2008-01-14 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
SG159525A1 (en) * 2005-04-26 2010-03-30 Glaxosmithkline Biolog Sa Vaccine
WO2008134934A1 (fr) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Protéine l1 tronquée du papillomavirus 16 humain
BRPI0815818A2 (pt) 2007-04-29 2016-08-02 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 truncada do papiloma vírus humano tipo 18
NO2403507T3 (Direct) * 2009-03-05 2018-07-21
PL2444103T3 (pl) * 2009-06-19 2018-05-30 Eyegene Inc. Szczepionka przeciwko rakowi szyjki macicy
CN106461667A (zh) 2014-01-31 2017-02-22 乌利塞生物医药公司 用于检测感染及相关病症的生物传感器
MX395186B (es) 2014-10-24 2025-03-21 Hpvvax Llc Vacuna de hpv para su uso en el tratamiento de cáncer de piel.
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
JPWO2016194685A1 (ja) * 2015-06-02 2018-03-29 テルモ株式会社 アルミニウムを含有するアジュバント組成物およびこれを含むワクチン組成物
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
SG11202008539YA (en) * 2018-03-06 2020-10-29 Precigen Inc Human papillomavirus vaccines and uses of the same
EP3812395A4 (en) * 2018-06-04 2022-03-30 Xiamen University MUTANT OF HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
EP1700911B1 (en) 1997-09-05 2016-04-06 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
SI1150712T1 (sl) * 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
ES2263637T3 (es) * 2000-06-26 2006-12-16 Stressgen Biotechnologies Corporation Hpv-e7 para el tratamiento del papilomavirus humano.

Also Published As

Publication number Publication date
TWI349557B (en) 2011-10-01
MXPA05006764A (es) 2005-09-08
CA2510457A1 (en) 2004-07-08
EA009179B1 (ru) 2007-12-28
KR20120123616A (ko) 2012-11-08
CY1111552T1 (el) 2015-08-05
IS7885A (is) 2005-06-09
IL169085A0 (en) 2007-07-04
JP5475939B2 (ja) 2014-04-16
AU2003293942B2 (en) 2009-12-10
TW200423957A (en) 2004-11-16
US20060251676A1 (en) 2006-11-09
BE2015C068I2 (Direct) 2024-08-08
KR20050086924A (ko) 2005-08-30
MA27581A1 (fr) 2005-10-03
EP1572233B1 (en) 2011-03-30
WO2004056389A1 (en) 2004-07-08
KR20120118087A (ko) 2012-10-25
BE2015C067I2 (Direct) 2024-08-08
ATE503492T1 (de) 2011-04-15
US20050287161A1 (en) 2005-12-29
BE2015C069I2 (Direct) 2024-08-08
CA2510457C (en) 2011-12-06
MY144492A (en) 2011-09-30
DE60336581D1 (de) 2011-05-12
DK1572233T3 (da) 2011-06-27
EA200500834A1 (ru) 2006-02-24
BR0317544A (pt) 2005-11-22
EP1572233A1 (en) 2005-09-14
ECSP055869A (es) 2005-09-20
OA13147A (en) 2006-12-13
IL169085A (en) 2014-04-30
PL377710A1 (pl) 2006-02-06
PL215257B1 (pl) 2013-11-29
AR042530A1 (es) 2005-06-22
HK1085378A1 (en) 2006-08-25
JP2006512413A (ja) 2006-04-13
AU2003293942A1 (en) 2004-07-14
KR101361769B1 (ko) 2014-02-10
NO20052846L (no) 2005-07-13
EA200701633A1 (ru) 2007-12-28
AP2005003347A0 (en) 2005-06-30
IS2811B (is) 2012-11-15
PT1572233E (pt) 2011-06-07

Similar Documents

Publication Publication Date Title
CA2510457C (en) Hpv-16 and -18 l1 vlp vaccine
JP2012102132A (ja) Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
CA2566620C (en) Vaccine against hpv16 and hpv18 and at least another hpv type slected from hpv 31, 45 or 52
CN100418577C (zh) Hpv-16和hpv-18l1vlp疫苗
KR20080005585A (ko) 백신
US7858098B2 (en) Vaccine
HK1085378B (en) Use of hpv16 and hpv18 as vaccine against one or more of oncogenic hpv type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
ES2361913T3 (es) Uso de hpv16 y hpv18 como vacunas con uno o más oncógenos de los tipos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
CN101217975A (zh) 疫苗
KR20080005583A (ko) 백신

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 DEC 2016 BY THOMSON REUTERS

Effective date: 20130920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 18 DEC 2023 BY HENRY HUGHES IP LIMITED

Effective date: 20140825

EXPY Patent expired